Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma
暂无分享,去创建一个
L. Gordon | M. Czuczman | J. Murray | T. Witzig | G. Wiseman | C. Emmanouilides | Antonio J. Grillo-López | P. Multani | C. White | D. Shen | A. Grillo‐López